Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 109

Sort by

Sort Order Select

Journal Articles

A pre-emptive bridge-to-transplant therapy for measurable residual disease with venetoclax and azacitidine in NPM1-mutated Acute Myeloid Leukemia: Updates from the ongoing GIMEMA AML2521 phase 2 trial

Blood (2025) 146 (Supplement 1): 3516.

https://doi.org/10.1182/blood-2025-3516

Published: 2025

Journal Articles

Different kinetic behavior of molecular reduction by BCR::ABL1 transcript types in frontline treatment of chronic myeloid leukemia patients: A GIMEMA labnet CML network database survey.

Blood (2025) 146 (Supplement 1): 3755.

https://doi.org/10.1182/blood-2025-3755

Published: 2025

Journal Articles

Molecular predictors of survival in patients with myeloproliferative neoplasm-blast Phase (MPN-BP) treated with venetoclax and decitabine

Paola Guglielmelli, Francesca Crupi, Mirko Lomi, Francesco Mannelli, Jessica Caroprese, Niccolò Bartalucci, Stefano Soddu, Chiara Maccari, Alessio Enderti, Daniele Colazzo, leonardo Signori, Giada Rotunno, Alfonso Piciocchi, Giuseppe Gaetano Loscocco, Sara Bianchini, Elena Nacca, Paola Fazi, Marco Vignetti, Alessandro Vannucchi

Blood (2025) 146 (Supplement 1): 3751.

https://doi.org/10.1182/blood-2025-3751

Published: 2025

Journal Articles

Venetoclax and decitabine in myeloproliferative neoplasm-blast Phase (MPN-BP): Results of enable, a gimema and airc-mynerva multicenter, Phase 2 trial

Blood (2025) 146 (Supplement 1): 1025.

https://doi.org/10.1182/blood-2025-1025

Published: 2025

Journal Articles

Mynerva-gimema AML1919 ameliorate Trial: EARLY intensification in FLT3-mutated ACUTE myeloid leukemia based on peripheral blast clearance

Blood (2025) 146 (Supplement 1): 5243.

https://doi.org/10.1182/blood-2025-5243

Published: 2025

Journal Articles

Health-related quality of life and symptom burden of patients with vexas: Real-world data from a multicenter observational study

Blood (2025) 146 (Supplement 1): 2685.

https://doi.org/10.1182/blood-2025-2685

Published: 2025

Journal Articles

International, prospective study comparing nilotinib versus imatinib with early switch to nilotinib to obtain sustained treatment-free remission (TFR) in patients with chronic myeloid leukemia: The tfr rate at the end of follow-up

Blood (2025) 146 (Supplement 1): 905.

https://doi.org/10.1182/blood-2025-905

Published: 2025

Journal Articles

First results of the Phase III GIMEMA ALL2820 trial comparing ponatinib plus blinatumomab to imatinib and chemotherapy for newly diagnosed adult ph+ acute lymphoblastic leukemia patients

Sabina Chiaretti, Mariangela Di Trani, Cristina Skert, Loredana Elia, Giada Almici, Irene Della Starza, Deborah Cardinali, Vittorio Bellomarino, Stefano Soddu, Monica Messina, Martina Rachele Marino, Maria Stefania De Propris, Erika Borlenghi, Francesco Di Raimondo, Michela Ansuinelli, Caterina Alati, Daniele G. Mattei, Valentina Mancini, Patrizia Chiusolo, Barbara Scappini, Maria Paola Martelli, Prassede Salutari, Marco Cerrano, Bianca Serio, Antonella Cucca, Mario Luppi, Daniele Vallisa, Crescenza Pasciolla, Claudio Romani, Martina Chiarucci, Federico Mosna, Massimiliano Bonifacio, Nicola Stefano Fracchiolla, Monica Bocchia, Silvia Imbergamo, Catello Califano, Giuseppe Rodolfo Nunziata, Mario Annunziata, Antonino Mule', Patrizia Zappasodi, Fabio Giglio, Daniela Pietrasanta, Matteo Della Porta, Maurizio Musso, Monia Lunghi, Francesco Zaja, Elisabetta Todisco, Claudia Maria Basilico, Alfonso Piciocchi, Paola Fazi, Alessandro Rambaldi, Robin Foà

Blood (2025) 146 (Supplement 1): 439.

https://doi.org/10.1182/blood-2025-439

Published: 2025

Journal Articles

Health-related quality of life trajectories of patients with aggressive B-cell lymphomas treated with CAR T-cell therapy: Results from a prospective observational study

Blood (2025) 146 (Supplement 1): 6279.

https://doi.org/10.1182/blood-2025-6279

Published: 2025

Journal Articles

The prognostic value of patient-reported fatigue for survival in patients with aggressive B-cell lymphomas treated with CAR T-cell therapy

Blood (2025) 146 (Supplement 1): 6278.

https://doi.org/10.1182/blood-2025-6278

Published: 2025

Journal Articles

Up-front blinatumomab improves MRD clearance and outcome in adult Ph – B-lineage ALL: the GIMEMA LAL2317 phase 2 study

Blood (2025) 145 (21): 2447–2459.

https://doi.org/10.1182/blood.2024027500

Published: 2025

Includes: Supplemental data

Journal Articles

Acute promyelocytic leukemia: long-term outcomes from the HARMONY project

Blood (2025) 145 (2): 234–243.

https://doi.org/10.1182/blood.2024026186

Published: 2025

Includes: Supplemental data

Journal Articles

Centralized MRD Assessment in Gimema AML1718 Trial, a Phase 2 Open-Label Study of Venetoclax Combined with Intensified FLAI Chemotherapy (V-FLAI) As Induction Therapy of Non Low-Risk AML

Blood (2024) 144 (Supplement 1): 1574.

https://doi.org/10.1182/blood-2024-198139

Published: 2024

Journal Articles

Factors Predicting Short-Term Symptom Burden in Patients with Aggressive B-Cell Lymphomas Treated with CAR T-Cell Therapy: A Real-World Study By the Gimema

Blood (2024) 144 (Supplement 1): 7823.

https://doi.org/10.1182/blood-2024-199498

Published: 2024

Journal Articles

Molecular Outcome of Chronic Myeloid Leukemia Affected Patients Not in Deep Molecular Response: The “Others” from the Gimema Labnet Network

Blood (2024) 144 (Supplement 1): 992.

https://doi.org/10.1182/blood-2024-210201

Published: 2024

Journal Articles

Digital Twins As Control Groups to Accelerate Assessment of Safety and Efficacy of Novel Treatment Strategies in Ph-Negative Acute Lymphoblastic Leukemia

Alfonso Piciocchi, Monica Messina, Giovanni Marsili, Marta Cipriani, Francesca Paola Paoloni, Davide Lazzarotto, Anna Candoni, Alessandro Rambaldi, Matteo Leoncin, Paola Fazi, Marco Vignetti, Robin Foà, Sabina Chiaretti

Blood (2024) 144 (Supplement 1): 274.

https://doi.org/10.1182/blood-2024-200643

Published: 2024

Journal Articles

Identification of Genomic Structural Variants (SVs) with Adverse Prognostic Significance in Normal-Karyotype (nk) Acute Myeloid Leukemia (AML) Patients

Blood (2024) 144 (Supplement 1): 65.

https://doi.org/10.1182/blood-2024-198342

Published: 2024

Journal Articles

Venetoclax and Azacitidine for Relapse Prevention in NPM1 -Mutated Acute Myeloid Leukemia in Molecular Failure: Results from the Ongoing Gimema AML2521 Phase 2 Trial

Blood (2024) 144 (Supplement 1): 2893.

https://doi.org/10.1182/blood-2024-210315

Published: 2024

Journal Articles

Survival Analysis of Gimema AML1718, a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia

Blood (2024) 144 (Supplement 1): 2891.

https://doi.org/10.1182/blood-2024-207842

Published: 2024

Journal Articles

ASXL1 Mutations at Diagnosis Did Not Impact on the Depth of Molecular Response (MR) and on Treatment-Free Remission (TFR) Eligibility in Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients (pts) Receiving either Nilotinib (NIL) First-Line or Imatinib (IM) with Early Switch to NIL in Case of No Optimal Response in the SUSTRENIM Clinical Trial

Blood (2024) 144 (Supplement 1): 3158.

https://doi.org/10.1182/blood-2024-205465

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

A pre-emptive bridge-to-transplant therapy for measurable residual disease with venetoclax and azacitidine in NPM1-mutated Acute Myeloid Leukemia: Updates from the ongoing GIMEMA AML2521 phase 2 trial

Different kinetic behavior of molecular reduction by BCR::ABL1 transcript types in frontline treatment of chronic myeloid leukemia patients: A GIMEMA labnet CML network database survey.

Molecular predictors of survival in patients with myeloproliferative neoplasm-blast Phase (MPN-BP) treated with venetoclax and decitabine

Venetoclax and decitabine in myeloproliferative neoplasm-blast Phase (MPN-BP): Results of enable, a gimema and airc-mynerva multicenter, Phase 2 trial

Mynerva-gimema AML1919 ameliorate Trial: EARLY intensification in FLT3-mutated ACUTE myeloid leukemia based on peripheral blast clearance

Health-related quality of life and symptom burden of patients with vexas: Real-world data from a multicenter observational study

International, prospective study comparing nilotinib versus imatinib with early switch to nilotinib to obtain sustained treatment-free remission (TFR) in patients with chronic myeloid leukemia: The tfr rate at the end of follow-up

First results of the Phase III GIMEMA ALL2820 trial comparing ponatinib plus blinatumomab to imatinib and chemotherapy for newly diagnosed adult ph+ acute lymphoblastic leukemia patients

Health-related quality of life trajectories of patients with aggressive B-cell lymphomas treated with CAR T-cell therapy: Results from a prospective observational study

The prognostic value of patient-reported fatigue for survival in patients with aggressive B-cell lymphomas treated with CAR T-cell therapy

Up-front blinatumomab improves MRD clearance and outcome in adult Ph – B-lineage ALL: the GIMEMA LAL2317 phase 2 study

Acute promyelocytic leukemia: long-term outcomes from the HARMONY project

Centralized MRD Assessment in Gimema AML1718 Trial, a Phase 2 Open-Label Study of Venetoclax Combined with Intensified FLAI Chemotherapy (V-FLAI) As Induction Therapy of Non Low-Risk AML

Factors Predicting Short-Term Symptom Burden in Patients with Aggressive B-Cell Lymphomas Treated with CAR T-Cell Therapy: A Real-World Study By the Gimema

Molecular Outcome of Chronic Myeloid Leukemia Affected Patients Not in Deep Molecular Response: The “Others” from the Gimema Labnet Network

Digital Twins As Control Groups to Accelerate Assessment of Safety and Efficacy of Novel Treatment Strategies in Ph-Negative Acute Lymphoblastic Leukemia

Identification of Genomic Structural Variants (SVs) with Adverse Prognostic Significance in Normal-Karyotype (nk) Acute Myeloid Leukemia (AML) Patients

Venetoclax and Azacitidine for Relapse Prevention in NPM1 -Mutated Acute Myeloid Leukemia in Molecular Failure: Results from the Ongoing Gimema AML2521 Phase 2 Trial

Survival Analysis of Gimema AML1718, a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only